Name | Number of supported studies | Average coverage | |
---|---|---|---|
natural killer cell | 41 studies | 55% ± 18% | |
CD16-negative, CD56-bright natural killer cell, human | 17 studies | 56% ± 21% | |
CD16-positive, CD56-dim natural killer cell, human | 17 studies | 62% ± 15% | |
mature NK T cell | 13 studies | 40% ± 18% | |
gamma-delta T cell | 8 studies | 23% ± 8% | |
innate lymphoid cell | 3 studies | 51% ± 21% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 4 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 98% | 67.16 | 87 / 89 | 74% | 3.35 | 665 / 901 |
lung | 100% | 221.71 | 577 / 578 | 56% | 1.94 | 652 / 1155 |
thymus | 95% | 48.01 | 620 / 653 | 61% | 2.53 | 369 / 605 |
uterus | 95% | 44.29 | 161 / 170 | 47% | 1.83 | 218 / 459 |
pancreas | 82% | 28.50 | 268 / 328 | 59% | 1.71 | 105 / 178 |
breast | 96% | 54.39 | 439 / 459 | 38% | 1.01 | 430 / 1118 |
ovary | 41% | 8.44 | 74 / 180 | 79% | 4.57 | 340 / 430 |
prostate | 89% | 42.84 | 218 / 245 | 26% | 0.42 | 130 / 502 |
liver | 95% | 68.28 | 215 / 226 | 18% | 0.38 | 73 / 406 |
bladder | 71% | 30.86 | 15 / 21 | 30% | 1.11 | 151 / 504 |
spleen | 100% | 908.94 | 241 / 241 | 0% | 0 | 0 / 0 |
stomach | 83% | 33.92 | 297 / 359 | 15% | 0.28 | 42 / 286 |
skin | 58% | 15.79 | 1046 / 1809 | 39% | 1.04 | 185 / 472 |
adipose | 97% | 61.57 | 1163 / 1204 | 0% | 0 | 0 / 0 |
esophagus | 68% | 21.02 | 989 / 1445 | 27% | 0.62 | 49 / 183 |
peripheral blood | 88% | 454.75 | 816 / 929 | 0% | 0 | 0 / 0 |
intestine | 74% | 29.65 | 718 / 966 | 13% | 0.23 | 68 / 527 |
brain | 57% | 14.56 | 1517 / 2642 | 20% | 0.34 | 143 / 705 |
heart | 73% | 22.75 | 625 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 67% | 1.64 | 30 / 45 |
blood vessel | 55% | 16.83 | 738 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 52% | 1.80 | 15 / 29 |
adrenal gland | 30% | 5.69 | 78 / 258 | 11% | 0.24 | 26 / 230 |
eye | 0% | 0 | 0 / 0 | 36% | 0.96 | 29 / 80 |
muscle | 26% | 4.63 | 209 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051132 | Biological process | NK T cell activation |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0032393 | Molecular function | MHC class I receptor activity |
GO_0030246 | Molecular function | carbohydrate binding |
Gene name | KLRF1 |
Protein name | Killer cell lectin-like receptor subfamily F member 1 (Lectin-like receptor F1) (Activating coreceptor NKp80) (C-type lectin domain family 5 member C) KLRF1 protein (Killer cell lectin like receptor F1) |
Synonyms | ML CLEC5C |
Description | FUNCTION: Involved in the natural killer (NK)-mediated cytolysis of PHA-induced lymphoblasts. |
Accessions | Q9NZS2 ENST00000537723.5 ENST00000279545.7 [Q9NZS2-2] Q4KMZ4 ENST00000354855.7 [Q9NZS2-3] Q4KN30 ENST00000617889.5 [Q9NZS2-1] ENST00000545196.1 Q4KN05 ENST00000617793.4 ENST00000612321.4 [Q9NZS2-4] |